Skip to main content

Table 5 Known-groups comparisons for the WHOQOL-BREF general facet and domain scores (n = 153)

From: Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the World Health Organization quality of life-BREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients

 

General Facet

Physical Health

Psychological Health

Social Relationships

Environment

n

Mean (SD)

P-value (effect size)*

n

Mean (SD)

P-value (effect size)*

n

Mean (SD)

P-value (effect size)*

n

Mean (SD)

P-value (effect size)*

n

Mean (SD)

P-value (effect size)*

Number of different adverse eventsa

 0–5

84

6.1 (1.7)

0.10

87

13.6 (3.1)

< 0.001 (0.08)

87

14.5 (2.5)

0.47

87

16.1 (2.7)

0.37

87

15.8 (2.2)

0.81

 more than 5

66

5.6 (1.8)

66

11.8 (2.9)

66

14.2 (2.6)

66

16.4 (2.4)

66

15.9 (2.4)

Number of different adverse events with CTCAE grade 3 or 4a

 0

112

6.0 (1.8)

0.16

115

13.1 (3.1)

0.06

115

14.4 (2.4)

0.93

115

16.1 (2.6)

0.36

115

15.8 (2.3)

0.82

 1

27

6.0 (1.8)

27

12.8 (3.0)

27

14.4 (2.8)

27

16.5 (2.6)

17.1 (2.2)

27

16.0 (2.3)

 2 or more

11

4.9 (1.4)

11

10.8 (2.6)

11

14.7 (2.9)

11

16.3 (2.5)

11

16.1 (2.6)

ECOG performance scoreb

          

16.5 (2.3)

    

 0

37

6.6 (1.5)

< 0.001 (0.08)

39

15.1 (2.3)

< 0.001 (0.23)

39

15.1 (2.2)

0.04 (0.04)

39

14.7 (3.5)

0.05

39

16.1 (1.8)

0.38

 1

98

5.7 (1.8)

99

12.3 (3.0)

99

14.3 (2.6)

99

 

99

15.9 (2.5)

 2 or more

13

4.8 (1.1)

13

10.2 (2.0)

13

13.1 (2.2)

13

 

13

15.1 (2.3)

Global health status/QoL EORTC QLQ-C30 score

 0–50

67

4.9 (1.5)

< 0.001 (0.30)

69

10.8 (2.7)

< 0.001 (0.36)

69

13.1 (2.6)

< 0.001 (0.22)

69

16.0 (2.8)

0.28

69

15.1 (2.4)

< 0.001 (0.10)

 more than 50

79

6.8 (1.4)

80

14.6 (2.3)

80

15.5 (1.9)

80

16.5 (2.3)

80

16.6 (2.0)

  1. Abbreviations: WHOQOL-BREF World Health Organization Quality of Life-BREF questionnaire, SD standard deviation, n number of patients who completed the questionnaire, CTCAE Common Terminology Criteria for Adverse Events, ECOG Eastern Cooperative Oncology Group, QoL quality of life, EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
  2. P-values calculated with one-way ANOVA unless stated otherwise
  3. *Effect sizes (η2) were only shown where one-way ANOVA was significant (P < 0.05).
  4. aReported adverse events: as reported at and before day 1 of the first cycle of chemotherapy
  5. bPost hoc analyses with Tukey HSD test of significant differences: for the General Facet, between ECOG 0 and 1 and also 0 and 2 or higher; for Physical Health, between all ECOG categories; for Psychological Health, between ECOG 0 and ECOG 2 or higher